36 patents
Utility
Systems and Methods for Producing Sterile Injection Devices
28 Dec 23
The present disclosure provides novel processes for providing sterile, pre-filled syringes or injection devices for pharmaceutical compositions, including protein and biopharmaceutical formulations.
Wendy SHIEU, Gerald LLORACH
Filed: 11 Sep 23
Utility
PPARy AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
13 Jul 23
Barbara Finck, David E. Weinstein, Sarita K. Jain
Filed: 7 Jan 22
Utility
Systems and Methods for Producing Sterile Injection Devices
29 Jun 23
The present disclosure provides novel processes for providing sterile, pre-filled syringes or injection devices for pharmaceutical compositions, including protein and biopharmaceutical formulations.
Wendy SHIEU, Gerald LLORACH
Filed: 21 May 21
Utility
Control Mechanism for Priming an Injection Device
27 Oct 22
An injection device includes a syringe barrel for holding medication, a collar positioned on a proximal end of the syringe barrel, a piston assembly including a piston arranged in the syringe barrel, and a rod member extending through the collar to the piston, and a blocking member arranged on the rod member.
Alasdair George Young, Gerald Llorach, Su Ann Teh, Dmitry Soyfertis, Brian Tachibana
Filed: 2 Oct 20
Utility
Compositions and Methods to Treat Non-alcoholic Fatty Liver Diseases (Nafld)
15 Sep 22
Provided herein are methods and combination therapies useful for the treatment of non-alcoholic fatty liver diseases (NAFLD).
Christos Mantzoros, Glenn D. Rosen
Filed: 27 Dec 19
Utility
Compositions and Methods to Treat Non-alcoholic Fatty Liver Diseases (Nafld)
15 Sep 22
Provided herein are methods and combination therapies useful for the treatment of non-alcoholic fatty liver diseases (NAFLD).
Christos Mantzoros, Glenn D. Rosen
Filed: 27 Dec 19
Utility
Compositions and Methods to Treat Cancer
30 Jun 22
Glenn D. Rosen
Filed: 26 May 20
Utility
Method of Producing a Recombinant Protein
23 Jun 22
Provided herein are methods of producing a recombinant protein that include fed-batch culturing a mammalian cell.
Robin Modi, James Russell Grove
Filed: 1 May 20
Utility
Compositions and Methods to Treat Non-alcoholic Fatty Liver Diseases (Nafld)
23 Jun 22
Provided herein are methods and combination therapies useful for the treatment of non-alcoholic fatty liver diseases (NAFLD).
Christos Mantzoros, Glenn D. Rosen
Filed: 27 Dec 19
Utility
Compositions and Methods to Treat Non-alcoholic Fatty Liver Diseases (Nafld)
23 Jun 22
Provided herein are methods and combination therapies useful for the treatment of non-alcoholic fatty liver diseases (NAFLD).
Christos Mantzoros
Filed: 27 Dec 19
Utility
Compositions and Methods to Treat Non-alcoholic Fatty Liver Diseases (Nafld)
9 Jun 22
Provided herein are methods and combination therapies useful for the treatment of non-alcoholic fatty liver diseases (NAFLD).
Christos Mantzoros, Glenn D. Rosen
Filed: 27 Dec 19
Utility
Compositions and Methods to Treat Non-alcoholic Fatty Liver Diseases (Nafld)
12 May 22
Provided herein are methods and combination therapies useful for the treatment of non-alcoholic fatty liver diseases (NAFLD).
Christos Mantzoros, Glenn D. Rosen
Filed: 27 Dec 19
Utility
Method of Filling a Container with No Headspace
10 Feb 22
The present invention is directed to methods for filling a container wherein the filled container has no headspace.
John Ogez, Jun Liu, Wenchang Ji, Patrick Daniel Begley, Isaias Prado, Mark Manning
Filed: 17 Jun 21
Utility
PPAR-gamma AGONIST FOR TREATMENT OF BLOOD CANCERS
9 Dec 21
Christos Mantzoros
Filed: 18 Aug 17
Utility
Stable Aqueous Formulations of Natalizumab
21 Oct 21
Described herein is a stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of natalizumab (optionally not subjected to prior lyophilization), a buffer effective to maintain the pH in the range from about 4.0 to about 7.0; and optionally, one or more surfactant{s), one or more amino acid(s), one or more sugar(s), one or more polyol(s), one or more chelating agent(s) (one or more polymer(s), one or more other stabilizing agent(s); and methods for making such a formulation; and methods of using such a formulation.
Mark Manning, Robert Walter Payne
Filed: 18 Jul 16
Utility
PPARy AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
16 Sep 21
Barbara Finck, David E. Weinstein, Sarita K. Jain
Filed: 3 Apr 18
Utility
Etanercept Formulations Exhibiting Marked Reduction In Sub-visible Particles
14 Jan 21
The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, with substantial reduction in sub-visible particles, and methods of manufacture of these compositions, methods of administration, and articles of manufacture.
Mark MANNING, Brian MURPHY, Douglas FARRAR, Alan HERMAN
Filed: 28 Sep 20
Utility
Etanercept Formulations Stabilized with Xylitol
30 Dec 20
The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
Mark MANNING, Brian Murphy
Filed: 13 Sep 20
Utility
Methods for the Treatment of Nonalcoholic Fatty Liver Disease And/or Lipodystrophy
9 Dec 20
The present invention relates to methods for treating a disease associated with insulin resistance selected from a nonalcoholic fatty liver disease (NAFLD) and its sequelae, a lipodystrophic syndrome or a combination thereof with the selective PPARγ agonist, INT131 and optionally vitamin E or compositions thereof.
Christos Mantzoros
Filed: 24 Jun 20
Utility
Stable Aqueous Formulations of Aflibercept
5 Aug 20
A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of aflibercept, wherein the formulation is free of organic co-solvent and/or free of buffer; methods for making such a formulation; and methods of using such a formulation.
Jun Liu, Mark Manning, Sekhar R. Kanapuram
Filed: 9 Sep 19